Skip to main content
Evidence Snapshot

Lacticaseibacillus casei

CHEMBL613075 ORGANISM Lacticaseibacillus casei
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613075
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lacticaseibacillus casei as ChEMBL target CHEMBL613075. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lacticaseibacillus casei
ORGANISM · Lacticaseibacillus casei
As of 2026-09-13
ChEMBL target ID
CHEMBL613075
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Lacticaseibacillus casei matters

As of 2026-09-13

Lacticaseibacillus casei is reviewed as Lacticaseibacillus casei; the current evidence base includes 5 approved drugs, 252 compounds, and 93 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 252 compounds, and 93 assays for this target. The dominant activity type is IC50. CHEMBL34259 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL34259 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Lacticaseibacillus casei matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

252
Total Compounds
93
Total Assays
5
Approved Drugs
IC50: 250.0, KI: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL34259
 11.0 IC50 Approved
No preferred name
CHEMBL1160189
 10.3 IC50 —
No preferred name
CHEMBL18925
 10.2 Ki —
No preferred name
CHEMBL293263
 10.1 IC50 —
No preferred name
CHEMBL1160188
 10.1 IC50 —

Approved Drugs

Structure Compound First Approval
TRIMETREXATE
CHEMBL119
 1993
TRIMETHOPRIM
CHEMBL22
 1973
METHOTREXATE
CHEMBL34259
 1953
PYRIMETHAMINE
CHEMBL36
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613075